Cohen R J, Robinson E, McRae C U
Department of Pathology, University of Auckland, New Zealand.
Aust N Z J Surg. 1997 Nov;67(11):781-4. doi: 10.1111/j.1445-2197.1997.tb04579.x.
Ageing male populations and improved diagnosis of early stage disease have contributed to the increasing incidence of prostate cancer observed in many Western countries. The clinical significance of these diagnosed cancers is, however, currently unclear. The aim of this study is to examine trends over time in prostate cancer mortality as an indicative measure of clinically significant disease during a 29-year period (1965-93) which preceded the extensive use of early cancer diagnostic techniques or radical therapy protocols.
Age-specific and age-standardized rates were calculated for each year during the study period, using routinely collected mortality and demographic data. A Poisson regression model was used to describe trends in the age-specific rates over time to predict numbers of prostate cancer deaths and the lifetime risk of death over the next 20 years.
Significant annual increases ranging from 1 to 2.6% were found for age-specific prostate cancer mortality rates over the 29-year time period, with the largest increases experienced in the younger age groups at risk. Based on projected population ageing and growth alone, annual numbers of prostate cancer deaths are predicted to increase from 487 in 1993 to 664 by the year 2006 and then to 833 by the year 2016. Continuation of the observed increases in age-specific mortality rates would result in a predicted 797 deaths by the year 2006, while an expected 1115 deaths is calculated for the year 2016. This would correspond with an increase in the lifetime risk of death from prostate cancer from a present 3.7 to 4.5% in 10 years and 6.2% in 20 years.
The changing pattern of prostate cancer mortality described in this study is likely to represent a significant increase in the incidence of clinically significant disease. This will have a significant impact on the ageing New Zealand male population, and important implications for the provision of effective treatment and preventive strategies.
男性人口老龄化以及早期疾病诊断水平的提高,导致许多西方国家前列腺癌发病率不断上升。然而,目前这些已确诊癌症的临床意义尚不清楚。本研究旨在探讨在早期癌症诊断技术或根治性治疗方案广泛应用之前的29年期间(1965 - 1993年),前列腺癌死亡率随时间的变化趋势,以此作为具有临床意义疾病的指示性指标。
利用常规收集的死亡率和人口统计学数据,计算研究期间每年的年龄别和年龄标准化率。采用泊松回归模型描述年龄别率随时间的变化趋势,以预测前列腺癌死亡人数以及未来20年的终生死亡风险。
在这29年期间,年龄别前列腺癌死亡率每年显著上升1%至2.6%,风险最大的年轻年龄组上升幅度最大。仅基于预计的人口老龄化和增长情况,前列腺癌死亡人数预计将从1993年的487例增加到2006年的664例,到2016年增至833例。如果年龄别死亡率继续保持观察到的上升趋势,预计到2006年将有797例死亡,而2016年预计为1115例。这将使前列腺癌的终生死亡风险从目前的3.7%在10年内增至4.5%,20年内增至6.2%。
本研究中描述的前列腺癌死亡率变化模式可能代表着具有临床意义疾病的发病率显著上升。这将对老龄化的新西兰男性人口产生重大影响,并对提供有效的治疗和预防策略具有重要意义。